JP2012144577A5 - - Google Patents

Download PDF

Info

Publication number
JP2012144577A5
JP2012144577A5 JP2012104795A JP2012104795A JP2012144577A5 JP 2012144577 A5 JP2012144577 A5 JP 2012144577A5 JP 2012104795 A JP2012104795 A JP 2012104795A JP 2012104795 A JP2012104795 A JP 2012104795A JP 2012144577 A5 JP2012144577 A5 JP 2012144577A5
Authority
JP
Japan
Prior art keywords
composition
component
trospium
trospium chloride
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012104795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012144577A (ja
JP5783489B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012144577A publication Critical patent/JP2012144577A/ja
Publication of JP2012144577A5 publication Critical patent/JP2012144577A5/ja
Application granted granted Critical
Publication of JP5783489B2 publication Critical patent/JP5783489B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

JP2012104795A 2003-11-04 2012-05-01 トロスピウムの１日１回剤形 Expired - Fee Related JP5783489B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51719803P 2003-11-04 2003-11-04
US60/517,198 2003-11-04
US52396803P 2003-11-21 2003-11-21
US60/523,968 2003-11-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006538425A Division JP5610663B2 (ja) 2003-11-04 2004-11-04 トロスピウムの１日１回剤形

Publications (3)

Publication Number Publication Date
JP2012144577A JP2012144577A (ja) 2012-08-02
JP2012144577A5 true JP2012144577A5 (enExample) 2015-01-22
JP5783489B2 JP5783489B2 (ja) 2015-09-24

Family

ID=34594857

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006538425A Expired - Fee Related JP5610663B2 (ja) 2003-11-04 2004-11-04 トロスピウムの１日１回剤形
JP2012104795A Expired - Fee Related JP5783489B2 (ja) 2003-11-04 2012-05-01 トロスピウムの１日１回剤形

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006538425A Expired - Fee Related JP5610663B2 (ja) 2003-11-04 2004-11-04 トロスピウムの１日１回剤形

Country Status (11)

Country Link
US (12) US7410978B2 (enExample)
EP (2) EP1680110B1 (enExample)
JP (2) JP5610663B2 (enExample)
AT (1) ATE493981T1 (enExample)
AU (1) AU2004289223B2 (enExample)
CA (1) CA2537103C (enExample)
DE (1) DE602004030931D1 (enExample)
DK (1) DK2210605T3 (enExample)
ES (1) ES2359375T3 (enExample)
PT (1) PT2210605T (enExample)
WO (1) WO2005046684A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046663A1 (en) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Compositions of quaternary ammonium containing bioavailability enhancers
DK2210605T3 (en) * 2003-11-04 2017-05-22 Tcd Royalty Sub Llc Daily single dose doses of trospium.
US20070134315A1 (en) * 2005-12-08 2007-06-14 Viera Michael L Orally administrable extended release pellet and tablet formulations of a highly water soluble compound
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
ATE525065T1 (de) * 2006-07-10 2011-10-15 Pfleger R Chem Fab Pharmazeutische zubereitung für die orale verabreichung mit gesteuerter wirkstofffreisetzung im dünndarm und verfahren zu ihrer herstellung
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
CN102114002B (zh) * 2006-12-04 2016-05-11 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
WO2009130712A2 (en) * 2008-04-22 2009-10-29 Lupin Limited Controlled release pharmaceutical compositions of trospium
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP3061821B1 (en) * 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
WO2011159824A1 (en) * 2010-06-16 2011-12-22 Allergan, Inc. Composition and method for treating overactive bladder
CN107080846A (zh) 2010-07-09 2017-08-22 詹姆斯.特林卡.格林 用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统
WO2012154774A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
WO2012154776A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of trospium and salivary stimulants for the treatment of overactive bladder
TW201722406A (zh) 2012-03-02 2017-07-01 羅德製藥公司 抗破壞性立即釋出型調製劑類
JP6055076B2 (ja) * 2012-03-23 2016-12-27 インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー．エル．エー．チャイナ シネフリン及びトピラマートを含む組み合わせ製品
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
MX358211B (es) * 2012-07-23 2018-08-10 Landsteiner Scient S A De C V Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
US8962020B2 (en) * 2012-07-26 2015-02-24 Glycadia Inc. Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid
US10751287B2 (en) * 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
CN104739808B (zh) * 2015-02-13 2017-09-22 舒泰神（北京）生物制药股份有限公司 一种曲司氯铵双释放胶囊及其制备方法
WO2017127073A1 (en) 2016-01-20 2017-07-27 Theravida, Inc. Methods and compositions for treating hyperhidrosis
IL281809B (en) 2018-09-28 2022-09-01 Karuna Therapeutics Inc Compositions and methods for the treatment of diseases improved by the activation of muscarinic receptors
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2899357A (en) * 1959-08-11 Oral pharmaceutical composition for
US518777A (en) * 1894-04-24 Bicycle
US652837A (en) * 1899-11-17 1900-07-03 Daniel Mcnamara Wheel for vehicles.
US2095282A (en) 1935-03-15 1937-10-12 Standard Oil Co Capillary viscometer
US2956926A (en) 1958-09-23 1960-10-18 American Cyanamid Co Coated citric acid particles
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
DE1194422B (de) * 1963-03-05 1965-06-10 Robert Pfleger Chem Fab Dr Verfahren zur Herstellung von Azoniaspironortropanderivaten
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
DE3237575A1 (de) 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
EP0193056B1 (de) 1985-02-23 1989-06-07 ASTA Pharma Aktiengesellschaft Kombination von Flupirtin und anticholinergisch wirkenden Spasmolytika
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
JP2528652B2 (ja) 1987-03-30 1996-08-28 エスエス製薬株式会社 持効性セフラジン製剤
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
GB8717446D0 (en) * 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5279660A (en) 1988-05-24 1994-01-18 Berol Nobel Stenungsund Ab Use of viscosity-adjusting agent to counteract viscosity decrease upon temperature increase of a water-based system
US5520932A (en) * 1988-06-24 1996-05-28 The Upjohn Company Fine-milled colestipol hydrochloride
US4970081A (en) * 1989-01-03 1990-11-13 Sterling Drug Inc. Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5372823A (en) 1989-03-16 1994-12-13 Bristol-Myers Squibb Company Direct compression cholestyramine tablet and solvent-free coating thereof
US5179660A (en) * 1989-05-15 1993-01-12 International Business Machines Incorporated System for reducing communications overhead in distributed database transactions by serializing in order related requests into single transmission message and receiving transmission response
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
WO1991016449A1 (en) * 1990-04-16 1991-10-31 The Trustees Of The University Of Pennsylvania Saccharide compositions, methods and apparatus for their synthesis
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5686094A (en) * 1991-04-01 1997-11-11 Theratech, Inc. Controlled release formulations for the treatment of xerostomia
US5095282A (en) * 1990-08-23 1992-03-10 Nvision, Inc. Differential amplifier apparatus
US5203203A (en) 1990-10-10 1993-04-20 Bryan William L Viscometer for in situ monitoring
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
WO1993006105A1 (en) * 1991-09-26 1993-04-01 United States Government, As Represented By Secret Substituted phenserines and phenylcarbamates of (-)-eseroline, (-)-n1-noreseroline, and (-)-n1-benzylnoreseroline; as specific inhibitors of acetylcholinesterase
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
DE69331378D1 (de) * 1992-02-18 2002-01-31 Nippon Shinyaku Co Ltd Verfahren zur Herstellung von schnelllöslicher Tabletten und schnelllöslichen Tablette beinhaltend Xylitol
US5405648A (en) * 1993-05-10 1995-04-11 Hermann; Paul F. Coating particulate material with a polymer film
WO1995005809A1 (en) * 1993-08-20 1995-03-02 Nippon Shinyaku Co., Ltd. Gastric remaining preparation, swollen molding, and production process
WO1995006462A1 (en) * 1993-08-30 1995-03-09 Warner-Lambert Company Tablet coating based on a melt-spun mixture of a saccharide and apolymer
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5520832A (en) * 1994-10-28 1996-05-28 Exxon Research And Engineering Company Tractor hydraulic fluid with wide temperature range (Law180)
JPH08157392A (ja) 1994-12-01 1996-06-18 Kanegafuchi Chem Ind Co Ltd 放出制御型製剤
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
FI98343C (fi) * 1995-03-21 1997-06-10 Orion Yhtymae Oy Peroraalinen formulaatio
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US5879712A (en) 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5779661A (en) * 1995-12-11 1998-07-14 Physion, S.R.L. Method of treating dysfunctional bladder syndromes by electromotive drug administration
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
JP3929522B2 (ja) * 1996-03-14 2007-06-13 塩野義製薬株式会社 難水溶性薬物の徐放性製剤
US6156340A (en) * 1996-03-29 2000-12-05 Duquesne University Of The Holy Ghost Orally administrable time release drug containing products
US20030064108A1 (en) * 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
US6652837B1 (en) * 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
JPH09315969A (ja) 1996-05-24 1997-12-09 Taiyo Yakuhin Kogyo Kk イブジラスト含有徐放性医薬品組成物及びその製造方法
EP0920313A1 (en) 1996-07-01 1999-06-09 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (s,s)-glycopyrrolate
US5959196A (en) 1996-09-10 1999-09-28 Norcross Corporation In-line viscometer
US20010003588A1 (en) 1996-09-12 2001-06-14 Smithkline Beecham Corporation Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
ATE172117T1 (de) * 1996-11-27 1998-10-15 Pfleger R Chem Fab Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten
US5973389A (en) * 1997-04-22 1999-10-26 International Business Machines Corporation Semiconductor chip carrier assembly
US6141624A (en) * 1997-05-13 2000-10-31 International Remote Imaging Systems Fluid sample for analysis controlled by total fluid volume and by total particle counts
IL128043A (en) 1997-05-30 2004-08-31 Osmotica Corp Multi-layered osmotic device for controlled delivery of active agents
US6141625A (en) 1997-06-09 2000-10-31 Dickey-John Corporation Viscometer module with crystal resonator-type sensor
DE19724696A1 (de) 1997-06-12 1998-12-24 Hexal Ag Pharmazeutische Zubereitung mit drei Pelletarten
US6197331B1 (en) 1997-07-24 2001-03-06 Perio Products Ltd. Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity
US6337091B1 (en) 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
CO5070568A1 (es) * 1998-05-22 2001-08-28 Eurand Internatrional Spa Proceso de aplicacion de capas y aparato para efectuarlo
AU4800999A (en) 1998-07-28 2000-02-21 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
JP2000103732A (ja) * 1998-07-28 2000-04-11 Tanabe Seiyaku Co Ltd 腸内適所放出型製剤
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
CZ302630B6 (cs) 1998-08-27 2011-08-10 Pharmacia & Upjohn Ab Farmaceutický prostredek obsahující tolterodin nebo tolterodinu príbuznou slouceninu
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
WO2000024423A1 (en) 1998-10-26 2000-05-04 Tanabe Seiyaku Co., Ltd. Sustained-release particles
US6270805B1 (en) 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
AU764469B2 (en) 1999-01-29 2003-08-21 Disphar International B.V. Pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
EP1064912B1 (de) 1999-07-02 2004-01-28 Cognis Iberia, S.L. Mikrokapseln - I
DE60036874T2 (de) * 1999-09-02 2008-06-26 Nostrum Pharmaceuticals Inc. Pellet formulierung mit gesteuerter freisetzung
BR0013719A (pt) * 1999-09-02 2002-07-23 Nostrum Pharmaceuticals Inc Dosagem oral de liberaçâo controlada, apropriada para administração oral
AU3104301A (en) 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
CA2398555C (en) 2000-01-27 2008-04-22 Tanabe Seiyaku Co., Ltd. Sustained release preparation and method for producing the same
PT1257277E (pt) 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc Novas combinacoes de farmacos
EP1272181A2 (en) 2000-04-13 2003-01-08 Synthon B.V. Modified release formulations containing a hypnotic agent
US6350471B1 (en) * 2000-05-31 2002-02-26 Pharma Pass Llc Tablet comprising a delayed release coating
JP4969761B2 (ja) 2000-08-31 2012-07-04 オバン・エナジー・リミテッド 所望粒度を持つ固体基材の小粒子および第一材料の小粒状物を含む相乗作用性混合物を製造する方法
US6620439B1 (en) * 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
SK287902B6 (sk) * 2001-01-31 2012-03-02 Evonik Rohm Gmbh Multiparticulate drug form and method for the preparation thereof
US6534088B2 (en) 2001-02-22 2003-03-18 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
AUPR752201A0 (en) * 2001-09-07 2001-09-27 Schefenacker Vision Systems Australia Pty Ltd Powered telescoping trailer tow mirror
ATE418534T1 (de) 2001-10-26 2009-01-15 Pharmacia & Upjohn Co Llc Quaternäre ammoniumverbindungen und deren verwendung als antimuscarinische wirkstoffe
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US6958161B2 (en) * 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
CA2483827C (en) 2002-04-29 2012-01-24 Amir H. Shojaei Pharmaceutical formulations with improved bioavailability
US7588825B2 (en) 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
US6974820B2 (en) * 2002-11-06 2005-12-13 Bridge Pharma, Inc. Methods for treating urinary incontinence and other disorders using trospium
EP1589951B1 (en) * 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
US20040138634A1 (en) 2003-01-10 2004-07-15 Litvay John D. Absorbent article having improved softness
ATE432070T1 (de) * 2003-01-22 2009-06-15 Pfizer Health Ab Herabgesetzte dosis von tolterodin zur behandlung von harnwegserkrankungen
US20040202693A1 (en) * 2003-04-14 2004-10-14 Rong-Kun Chang Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
EP1622450A4 (en) * 2003-04-25 2009-11-18 Endo Pharmaceuticals Solutions PROCESS FOR PROMOTING UNINTERRUPTED SLEEP BY ADMINISTERING TROPIUM CHLORIDE
US6772801B1 (en) 2003-05-14 2004-08-10 Shire Laboratories, Inc. Fluidization of particles for encapsulation in oral dosage pharmaceutical products
DK2210605T3 (en) * 2003-11-04 2017-05-22 Tcd Royalty Sub Llc Daily single dose doses of trospium.
EP1788939A4 (en) * 2004-09-08 2009-11-25 Univ Ramot MRI PRESENTATION AND CONTRAST METHOD
JP2006146117A (ja) * 2004-10-20 2006-06-08 Brother Ind Ltd 画像形成装置

Similar Documents

Publication Publication Date Title
JP2007510656A5 (enExample)
ES2708955T5 (es) Formulaciones orales de deferasirox
ES2524408T3 (es) Composiciones terapéuticas que comprenden rilpivirina HCl y tenofovir disoproxil fumarato
JP5911969B2 (ja) 心臓血管障害の治療方法
JP2011513391A (ja) ミコフェノラートを含有する徐放性医薬組成物およびその方法
KR20110008036A (ko) 약 염기성 약물 및 제어 방출 제형을 포함하는 조성물
PT760655E (pt) Forma de dosagem farmaceutica de libertacao controlada em multicamadas
KR20150132399A (ko) 에베롤리무스를 포함하는 제약 조성물
WO2009090670A2 (en) Stabilized sustained release composition of bupropion hydrochloride and process for preparing the same
CN103874484A (zh) 包含40-o-(2-羟基)乙基-雷帕霉素的药物组合物
RU2014140177A (ru) Фармацевтические антиретровирусные композиции
CN113423390B (zh) 阿法比星制剂及其制备方法
JP2009517466A5 (enExample)
JP2014533656A5 (enExample)
CA2537103A1 (en) Once daily dosage forms of trospium
EP3843706A1 (en) Vitamin d pediatric dosage forms, methods of making and using
CN103402501A (zh) 调节释放的苯并咪唑制剂
CN109890372B (zh) 含埃索美拉唑的复合胶囊及其制备方法
TW201410267A (zh) 延長釋放左乙拉西坦和製備方法
WO2009097156A1 (en) Pharmaceutical capsules comprising extended release dipyridamole pellets
KR20150127253A (ko) 구토억제 서방형 고체 제형
JP6236079B2 (ja) ３種の活性成分を含有する新規な時差放出医薬組成物
WO2009087690A2 (en) Multiparticulate extended release pharmaceutical composition of carbamazepine and process for manufacturing the same
CN103142518B (zh) 一种阿格列汀脂质体固体制剂及其制备方法和应用
HK40006608A (en) Esomeprazole-containing complex capsule and preparation method therefor